Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors

被引：0

作者：

Liepelt, I. ^{[1
]}

Maetzler, W. ^{[1
]}

Blaicher, H. -P. ^{[2
]}

Gasser, T. ^{[1
]}

Berg, D. ^{[1
]}

机构：

[1] Hertie Inst Klin Hirnforschung, Abt Neurol Schwerpunkt Neurodegenerat Erkrankunge, D-72076 Tubingen, Germany

[2] Univ Tubingen, Klin Psychiat & Psychotherapie, D-72074 Tubingen, Germany

来源：

NERVENARZT | 2008年 / 79卷 / 01期

关键词：

cholinesterase inhibitors; dementia; lewy body disease; parkinsonian syndromes; therapy;

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

In parkinsonian syndromes dementia frequently occurs in the disease progress. The cholinergic system has been proposed as playing a key role in cognitive disturbances. Therefore the application of cholinesterase inhibitors (ChEI) is also hotly argued for dementia associated with parkinsonian syndromes. This review focuses on the specific symptoms of dementia in Parkinson's disease (PDD), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). The effect of cholinergic treatment on cognition and behaviour is reported and critically discussed. There is evidence that medication with some ChEIs reduces cognitive disturbances and to a lesser extent improves activities of daily living in PDD. Behavioural symptoms also seem to be positively influenced by treatment with ChEIs in both PDD and DLB. The effect of treatment with cholinesterase inhibitors in PSP and CBD warrants more carefully designed studies including sufficient numbers of patients.

引用

页码：36 / +

页数：9

共 50 条

[21] Cholinesterase inhibitors for the treatment of dementia in Parkinson's disease
Holdorff, B.
NERVENARZT, 2008, 79 (09): : 1076 - 1076
[22] A comparison of cholinesterase inhibitors for treatment of dementia with Lewy bodies
Edwards, Keith R.
Bhasin, Mani
Rowan, Elise
McKeith, Ian
NEUROLOGY, 2007, 68 (12) : A122 - A122
[23] Preclinical efficacy of NLRP3 small molecule inflammasome inhibitors: Implications for future treatment of autoinflammatory syndromes.
Abad-Perez, A.
Frischbutter, S.
Mahnke, N. A.
Kries, J. V.
Nazare, M.
Maurer, M.
Scheffel, J.
Krause, K.
EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E51 - E52
[24] Cholinesterase inhibitors for agitation in dementia
Wilkinson, D
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (11) : 1085 - 1085
[25] Economics of cholinesterase inhibitors for dementia
不详
PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2009, 13 (06) : 41 - 42
[26] Efficacy of Cholinesterase Inhibitors in Vascular Dementia: An Updated Meta-Analysis
Chen, Yu-dan
Zhang, Juan
Wang, Yue
Yuan, Jun-liang
Hu, Wen-li
EUROPEAN NEUROLOGY, 2016, 75 (3-4) : 132 - 141
[27] Comparative efficacy of cholinesterase inhibitors in dementia associated with Parkinson's disease
Vasile, D.
Vasiliu, O.
Mangalagiu, A. G.
Blandu, M.
Nanca, A.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 174 - 174
[28] Efficacy of topiramate in children with congenital syndromes.
Levisohn, PM
EPILEPSIA, 1999, 40 : 68 - 68
[29] Efficacy of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis
Kani, C.
Papanikolaou, K.
Pehlivanidis, A.
Papadopoulou-Daifoti, Z.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S505 - S505
[30] Comparative efficacy of cholinesterase inhibitors in dementia associated with Parkinson's disease
Vasile, D.
Vasiliu, O.
Vasile, M. L.
Terpan, M.
Grigorescu, G.
Bogdan, V.
Mangalagiu, A.
Petrescu, M. B.
Ojog, D.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S553 - S554

← 1 2 3 4 5 →